- 首頁
- Cannabinoid Receptor
- (R)-SLV 319
(R)-SLV 319
The inactive enantiomer of SLV 319
此產品僅用于科學研究，我們不為任何個人用途提供產品和服務
-
包裝價格促銷價數量
-
1mg￥1350.001080.00- +
-
5mg￥5337.004270.00- +
-
10mg￥8025.006420.00- +
- 貨號: ajci4298
- CAS: 656827-86-0
- 別名:
- 分子式: C23H20Cl2N4O2S
- 分子量: 487.4
- 純度: ＞98%
- 溶解度: ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
- 儲存: Store at -20°C
- 庫存: 現貨
Background
Ki: 7.8 and 7943 nM for CB1 and CB2 receptors, respectively by SLV 319
(R)-SLV 319 is a CB1 receptor antagonist.
Central cannabinoid (CB1) receptor antagonists can be used in the treatment of various diseases including cognitive disorders, neuroinflammatory disorders, obesity, septic shock, psychosis, addiction, as well as gastrointestinal disorders.
In vitro: (R)-SLV 319 is the inactive enantiomer of SLV 319 with 100-fold less affinity for the CB1 receptor. SLV 319 was identified as a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and peripheral cannabinoid (CB2) receptors, respectively. SLV 319 was found to be less lipophilic and thus more water soluble than other known CB1 receptor ligands [1,2].
In vivo: A previous animal study examined the chronic effects of SLV 319 in hyperinsulinemic Zucker rats to determine their chronic effects on insulinemia. Results showed that R SLV 319 at 10 mg·kg-1·day-1 elicited body weight-independent improvements in insulinemia and glycemia during 10 wk of chronic treatment. Moreover, SLV 319 treatment caused glucose intolerance in CB1 but not SUR1-KO mice [3].
Clinical trial: So far, no clinical study has been conducted.
參考文獻:
[1] Lange, J.?H.M.,Coolen, H.K.A.C.,van Stuivenberg, H.H., et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. Journal of Medicinal Chemistry 47(3), 627-643 (2004).
[2] Lange, J.?H.M.,van Stuivenberg, H.H.,Veerman, W., et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorganic & Medicinal Chemistry Letters 15, 4794-4798 (2005).
[3] Lynch CJ, Zhou Q, Shyng SL, Heal DJ, Cheetham SC, Dickinson K, Gregory P, Firnges M, Nordheim U, Goshorn S, Reiche D, Turski L, Antel J.?Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. Am J Physiol Endocrinol Metab. 2012 Mar 1;302(5):E540-51.
